Wound Care Plus, LLC Adopts MolecuLight i: X® as the Standard Point-of-Care Device for Long-Term and Advanced Care Wound Care | message

The MolecuLighti:X provides critical real-time information to assist Wound Care Plus wound care advisors in providing high quality wound care

TORONTO and BLUE SPRINGS, Mo, Dec 12 2020 / PRNewswire / – MolecuLight Inc., the leader in bedside fluorescence imaging for real-time detection of bacteria in wounds, announced that Wound Care Plus, LLC, the largest mobile wound care provider in the US Midwest, has launched MolecuLighti:X Point of care imaging device. The device is intended to be used as standard for long-term care and extended care facilities.

Long-term care facilities have a disproportionately high prevalence of wounds and related infections compared to the general population. (1) Skin and soft tissue infections are the third most common infection in this area, with a high incidence rate of up to 2.1 cases / 1000 days of care. (2) Infections often develop in these wounds because the high bacterial load is often recognized too late in this immunocompromised patient group, in which the signs and symptoms of infection are suppressed. Early detection of clinically significant levels of bacteria can limit the development of invasive or systemic infections in this vulnerable patient population.

?? We are pleased to announce that Wound Care Plus, LLC has launched the MolecuLighti:X after thoroughly evaluating our technology as the standard for caring for their customers in long-term care and extended care facilities in 14 states, says Anil Amlani, CEO by MolecuLight. ?? This again shows how well the MolecuLight works i:X Device complements clinical decision-making of wound care professionals – and helps improve clinical outcomes in long-term care and extended care facilities. “

“Quality wound care is essential in long-term care and extended care,” says Martha R. Kelso RN, LNC, HBOT, Founder and Chief Executive Officer of Wound Care Plus, LLC. We are often called into long-term care and extended care facilities to treat chronic, non-healing wounds in clients with multiple severe comorbidities and polypharmacy. This usually happens after several failed standard therapies. Our most vulnerable customers deserve the best care and resources we can offer. Better diagnostic tools and advanced procedures improve our success in wound healing and reduce the need for amputation or premature death. Detection of bacteria at the customer’s bedside with the MolecuLight i:X has changed the way we care for our customers’ wounds. There is no guesswork or waiting for cultures to identify the bacterial load in the wound. The information we received about wound fluorescence led to changes in the treatment plan in over 80% of the wounds examined. We often use targeted debridement to remove the bacteria and non-viable tissue without to reach for antibiotics right away. Imaging with the MolecuLight i:X gives us instant information that will help us determine whether the bacteria have been effectively removed or whether additional treatment is needed. “

The MolecuLight i:X will become a standard care tool developed by Wound Care Plus Wound Consultants in all offices in Arkansas, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Missouri, Nebraska, New York, Ohio, Oklahoma, Texas and Wisconsin is deployed and provides real-time insight into the wounds of hundreds of thousands of customers in long-term care and extended care facilities. The picture on the right shows a MolecuLight i:X Image of a Wound Care Plus client’s wound taken at the treatment site. Cyan fluorescence was observed on the image of the wound. The microbiological examination of the smear then indicated the presence of Pseudomonas. This real-time information supports the wound consultant in treating the wound. He decided to continue debriding the wound to remove the problematic bacteria and not prescribe antibiotics. If we can avoid antibiotics, we will prevent the unnecessary weakening of our already fragile customers from these drugs, and also prevent the further spread of antibiotic resistance that is rampant in the healthcare sector. The introduction of the MolecuLighti:X Point-of-care imaging equipment for our aging and elderly population suffering from a chronic wound is an important improvement in wound healing, “affirmed Kelso.

The MolecuLight i:X imaging procedures has a reimbursement mode that includes two CPT® codes. The doctor can use this for his work in the field of long-term care and extended care for his work in carrying out the ??Fluorescence wound imaging to analyze the presence of bacteria, their location and amount“apply.

About MolecuLight Inc.

MolecuLight Inc. is a privately held medical imaging company that has developed and commercialized its proprietary fluorescence imaging platform technology in multiple clinical markets. MolecuLight’s first commercially released device, the MolecuLight fluorescence imaging system i:X, and its accessories provide the global wound care market with a hand-held point-of-care imaging device for the detection of wounds with elevated bacterial load (when used with clinical signs and symptoms) and digital wound measurement. The company also commercializes its unique fluorescence imaging platform technology to other markets with globally relevant, unmet needs, including food safety, consumer cosmetics and other key industrial markets.

About Wound Care Plus, LLC

Wound Care Plus, LLC is the largest mobile wound care provider in the Midwest USA with branches in Arkansas, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Missouri, Nebraska, New York, Ohio, Oklahoma, Texas and Wisconsin. Our specialists at the Advanced Mobile Wound Clinic diagnose wound and skin diseases, offer treatments and procedures; they are “the next-generation wound specialist that comes to you!”. Wound Care Plus LLC provides services to long-term / care facilities, acute hospitals, wound centers, nursing homes, residential homes and assisted living facilities. They help care facilities be better, more complete To offer care, because in addition to the primary care of wounds and skin diseases of customers, they also offer training, documentation and advice for wound care programs and quality assurance tests.

Logo – https://mma.prnewswire.com/media/1372690/MolecuLight_Wound_Care_Plus__LLC_Adopts_the_MolecuLight_i_X__as.jpg

Rob Sandler, Chief Marketing Officer, MolecuLight Inc., T. +1 647-362-4684, [email protected], www.moleculight.com; Martha R. Kelso, Chief Executive Officer, Wound Care Plus, LLC, T. 888.256.3814, [email protected], www.mywoundcareplus.com

–